LENSAR
LENSAR's revenue rose 9.2% to $58 million in fiscal 2025. Its operating margin was −42.1%, down from −19.9% a year earlier. Free cash flow was −$15 million. The diluted share count rose 3.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
LENSAR lost money in fiscal 2025: a net loss of $34 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 32 | 15 | 24 | 22 | 18 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 5.1x | 3.0x | 4.0x | 2.8x | 1.1x |
| Quick ratio | 4.4x | 1.9x | 2.6x | 2.0x | 0.6x |
Cash flow
Projections
Project LENSAR's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought LENSAR shares on the open market, and 1 insider sold $169,989.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | Elizabeth G. O'FarrellDirector | Sold | 10,961 | $4.97 | $54,476 | Form 4 |
| Nov 17, 2026 | Elizabeth G. O'FarrellDirector | Sold | 22,214 | $5.20 | $115,513 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −4.2% | 22.3% | −16.3% |
| Altman Z'' | −1.57 | −5.35 | −10.17 |
| Accruals ratio | −7.5% | −42.9% | −28.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put LENSAR side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| LENSAR | FY25 | 9.2% | −42.1% | −25.5% | — | — | — | |
| CVRx | FY25 | 10.4% | −90.5% | −71.9% | −294.3% | — | 3 | Compare |
| Apyx Medical | FY25 | 9.9% | −12.2% | −17.2% | −25.0% | — | 4 | Compare |
| IRIDEX | FY25 | 8.2% | −4.9% | −4.3% | — | — | — | Compare |
| Carlsmed | FY25 | 85.9% | −60.5% | −58.6% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 30 | 26 | 34 | 35 | 42 | 54 | 58 |
| Revenue growth | — | −13.6% | 30.6% | 2.6% | 19.2% | 26.9% | 9.2% |
| Gross profit | 13 | 14 | 18 | 20 | 21 | 26 | 27 |
| Research and development | 8 | 8 | 12 | 12 | 6 | 5 | 6 |
| Operating income | −13 | −18 | −20 | −20 | −12 | −11 | −25 |
| Net income | −15 | −20 | −20 | −20 | −14 | −31 | −34 |
| Diluted EPS (US$) | −13.70 | −4.28 | −2.09 | −1.96 | −1.31 | −2.73 | −2.87 |
| Diluted shares (millions) | 1 | 5 | 9 | 10 | 11 | 12 | 12 |
| Cash flow | |||||||
| Cash from operations | −13 | −14 | −9 | −15 | −10 | −2 | −15 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −13 | −14 | −9 | −15 | −10 | −2 | −15 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 9 | 7 | 7 | 6 | 3 | 3 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 5 | 41 | 32 | 15 | 24 | 22 | 18 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | 34 | 79 | 66 | 56 | 70 | 66 | 71 |
| Total liabilities | 65 | 12 | 12 | 14 | 22 | 48 | 84 |
| Shareholders' equity | −31 | 67 | 55 | 42 | 33 | 5 | −26 |
| Margins and ratios | |||||||
| Gross margin | 43.3% | 53.4% | 51.8% | 56.4% | 50.1% | 48.3% | 46.4% |
| Operating margin | −41.6% | −70.1% | −57.0% | −57.1% | −29.0% | −19.9% | −42.1% |
| Net margin | −48.0% | −75.0% | −56.9% | −56.3% | −34.1% | −58.7% | −58.7% |
| Free cash flow margin | −42.5% | −53.7% | −27.1% | −42.3% | −23.5% | −4.5% | −25.5% |
| Rule of 40 (growth + FCF margin) | — | −67.2% | 3.6% | −39.7% | −4.2% | 22.3% | −16.3% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | −107.9% | −32.1% | −41.1% | −38.1% | −164.0% | — |
| Return on assets | — | −34.8% | −26.9% | −32.6% | −22.9% | −46.2% | −49.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — |